Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic leukemia in first complete remission, but the optimal strategy remains controversial. There are no randomized trials of allogeneic HCT. In the present study, updated individual patient data were collected and analyzed from studies with information on availability of matched sibling donor (used to mimic randomization) and from randomized trials of autograft versus chemotherapy. Data from 13 studies including 2962 patients, excluding Philadelphia chromosome-positive patients, showed a survival benefit for having a matched sibling donor for patients < 35 years of age (OR = 0.79; 95% CI, 0.70-0.90, P = .0003) but not for those ≥ 35 years of age (OR = 1.01; 95% CI, 0.85-1.19, P = .9; heterogeneity P = .03) because of the higher absolute risk of nonrelapse mortality for older patients. No differences were seen by risk group. There was a trend toward inferior survival for autograft versus chemotherapy (OR = 1.18; 95% CI, 0.99-1.41; P = .06). No beneficial effect of autografting was seen compared with chemotherapy in this analysis. We conclude that matched sibling donor myeloablative HCT improves survival only for younger patients, with an absolute benefit of approximately 10% at 5 years. Improved chemotherapy outcomes and reduced nonrelapse mortality associated with allogeneic HCT may change the relative effects of these treatments in the future.

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: An individual patient data meta-analysis / Gupta, V; Richards, S; Rowe, J; Büchner, T; Hiddemann, W; Sauerland, C; Amadori, S; Rondelli, R; Testi, Am; Attal, M; Jourdan, E; Reiffers, J; Howman, A; Patel, S; Jacobs, P; Lee, S; Brunet, S; Sierra, J; Alonzo, T; Aplenc, R; Sung, L; Cutler, C; Rowe, J; Sun, Z; Tallman, M; Ljungman, P; Labar, B; Willemze, R; Suciu, S; Collette, S; Dombret, H; Thomas, X; Ifrah, N; Hunault-Berger, M; Mandelli, F; Vignetti, M; Tsimberidou, Am; Pagnano, K; da Souza, Ca; Miranda, Ec; Diaz de Heredia, C; Ortega, Jj; Cornelissen, Jj; van der Holt, B; Oh, H; Takeuchi, J; Kaizer, H; Björkholm, M; Rosenborg, A; Keating, M; Zander, A; Fielding, A; Goldstone, A; Moorman, Av; Richards, S; Bassan, R; Ravindranath, Y; Weinstein, H; Oriol, A; Ribera, Jm; Powles, R; Appelbaum, F; Baker, Luigi; Coltman, C; Crowley, J; Kopecky, K; Messner, H; Gupta, V; Akan, H; Beksac, M; Hills, R; Buck, G; Davies, K; Elphinstone, T; Evans, V; Gettins, L; Gregory, C; James, S; Mackinnon, L; Mchugh, T; Morris, P; Richards, S; Wade, R; Wheatley, K.. - In: BLOOD. - ISSN 0006-4971. - 121:2(2013), pp. 339-350. [10.1182/blood-2012-07-445098]

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: An individual patient data meta-analysis

Amadori S;Testi AM;Mandelli F;Vignetti M;BAKER, Luigi;Crowley J;
2013

Abstract

Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic leukemia in first complete remission, but the optimal strategy remains controversial. There are no randomized trials of allogeneic HCT. In the present study, updated individual patient data were collected and analyzed from studies with information on availability of matched sibling donor (used to mimic randomization) and from randomized trials of autograft versus chemotherapy. Data from 13 studies including 2962 patients, excluding Philadelphia chromosome-positive patients, showed a survival benefit for having a matched sibling donor for patients < 35 years of age (OR = 0.79; 95% CI, 0.70-0.90, P = .0003) but not for those ≥ 35 years of age (OR = 1.01; 95% CI, 0.85-1.19, P = .9; heterogeneity P = .03) because of the higher absolute risk of nonrelapse mortality for older patients. No differences were seen by risk group. There was a trend toward inferior survival for autograft versus chemotherapy (OR = 1.18; 95% CI, 0.99-1.41; P = .06). No beneficial effect of autografting was seen compared with chemotherapy in this analysis. We conclude that matched sibling donor myeloablative HCT improves survival only for younger patients, with an absolute benefit of approximately 10% at 5 years. Improved chemotherapy outcomes and reduced nonrelapse mortality associated with allogeneic HCT may change the relative effects of these treatments in the future.
Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Transplantation, Autologous; Transplantation, Homologous; Young Adult; Hematology; Biochemistry; Cell Biology; Immunology
01 Pubblicazione su rivista::01a Articolo in rivista
Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: An individual patient data meta-analysis / Gupta, V; Richards, S; Rowe, J; Büchner, T; Hiddemann, W; Sauerland, C; Amadori, S; Rondelli, R; Testi, Am; Attal, M; Jourdan, E; Reiffers, J; Howman, A; Patel, S; Jacobs, P; Lee, S; Brunet, S; Sierra, J; Alonzo, T; Aplenc, R; Sung, L; Cutler, C; Rowe, J; Sun, Z; Tallman, M; Ljungman, P; Labar, B; Willemze, R; Suciu, S; Collette, S; Dombret, H; Thomas, X; Ifrah, N; Hunault-Berger, M; Mandelli, F; Vignetti, M; Tsimberidou, Am; Pagnano, K; da Souza, Ca; Miranda, Ec; Diaz de Heredia, C; Ortega, Jj; Cornelissen, Jj; van der Holt, B; Oh, H; Takeuchi, J; Kaizer, H; Björkholm, M; Rosenborg, A; Keating, M; Zander, A; Fielding, A; Goldstone, A; Moorman, Av; Richards, S; Bassan, R; Ravindranath, Y; Weinstein, H; Oriol, A; Ribera, Jm; Powles, R; Appelbaum, F; Baker, Luigi; Coltman, C; Crowley, J; Kopecky, K; Messner, H; Gupta, V; Akan, H; Beksac, M; Hills, R; Buck, G; Davies, K; Elphinstone, T; Evans, V; Gettins, L; Gregory, C; James, S; Mackinnon, L; Mchugh, T; Morris, P; Richards, S; Wade, R; Wheatley, K.. - In: BLOOD. - ISSN 0006-4971. - 121:2(2013), pp. 339-350. [10.1182/blood-2012-07-445098]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1189544
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 99
  • ???jsp.display-item.citation.isi??? 96
social impact